CG
LGND icon

Cutler Group’s Ligand Pharmaceuticals LGND Stock Holding History

Cutler Group’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-2,725
Closed -$177K – 4388
2019
Q4 		$177K Buy
+2,725
New +$182K 0.01% 884
2018
Q1 		– Sell
-231
Closed -$19K – 4875
2017
Q4 		$19K Hold
231
– – ﹤0.01% 2605
2017
Q3 		$19K Buy
+231
New +$18.3K ﹤0.01% 3181
2017
Q2 		– Sell
-7,573
Closed -$530K – 6731
2017
Q1 		$499K Sell
7,573
-17,586
-70% -$1.16M 0.02% 643
2016
Q4 		$1.59M Buy
25,159
+19,137
+318% +$1.21M 0.06% 256
2016
Q3 		$383K Buy
6,022
+5,642
+1,485% +$414K 0.02% 753
2016
Q2 		$28K Sell
380
-792
-68% -$58.8K ﹤0.01% 3005
2016
Q1 		$78K Buy
1,172
+590
+101% +$35.9K 0.01% 1862
2015
Q4 		$39K Buy
+582
New +$35.9K ﹤0.01% 2727

Other funds holding LGND

William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CCMLC
Cardinal Capital Management LLC (Connecticut) Greenwich, Connecticut $365M AUM 18.32% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
CCA
Conestoga Capital Advisors Wayne, Pennsylvania $5.01B AUM 6.26% 1-Year Est. Return
SDJVC
St. Denis J. Villere & Co New Orleans, Louisiana $907M AUM 10.61% 1-Year Est. Return

Cutler Group's LGND Position: Q1 2020 in Review

Cutler Group sold out of Ligand Pharmaceuticals (LGND) in Q1 2020, closing a stake of 2,725 shares — an estimated $177K sold.

Cutler Group first reported a position in LGND in Q4 2015 and held it in 9 quarters. The position peaked at $1.59M in Q4 2016. 262 funds tracked by Wall St. Rank hold LGND as of Q1 2020.

  • Cutler Group reported no remaining Ligand Pharmaceuticals position as of Q1 2020 after selling out during the quarter.
  • Cutler Group sold 2,725 Ligand Pharmaceuticals shares in Q1 2020, an estimated $177K.
  • Cutler Group first reported a position in Ligand Pharmaceuticals in Q4 2015 and held it in 9 quarters.
  • Cutler Group's Ligand Pharmaceuticals position peaked at $1.59M in Q4 2016.
  • 262 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q1 2020.

Based on Cutler Group's 13F filing for Q1 2020, filed 7 May 2020.